| Primary |
| Acute Leukaemia |
80.0% |
| Hodgkin's Disease Recurrent |
20.0% |
|
| Neutropenic Sepsis |
33.3% |
| Rash |
33.3% |
| Unevaluable Event |
33.3% |
|
| Secondary |
| Diffuse Large B-cell Lymphoma |
42.3% |
| Product Used For Unknown Indication |
7.4% |
| Neuroblastoma |
7.0% |
| Acute Lymphocytic Leukaemia |
6.4% |
| B-cell Lymphoma |
6.2% |
| Plasma Cell Myeloma |
4.9% |
| Prophylaxis |
3.1% |
| Mantle Cell Lymphoma |
2.9% |
| Acute Myeloid Leukaemia |
2.6% |
| Ewing's Sarcoma |
2.1% |
| Drug Use For Unknown Indication |
1.8% |
| Haematopoietic Stem Cell Mobilisation |
1.7% |
| Malignant Lymphoid Neoplasm |
1.6% |
| Follicle Centre Lymphoma, Follicular Grade I, Ii, Iii |
1.5% |
| Hypertension |
1.5% |
| Acute Myeloid Leukaemia Recurrent |
1.5% |
| Myelodysplastic Syndrome |
1.5% |
| Nausea |
1.3% |
| Systemic Sclerosis |
1.2% |
| Cardiac Failure |
1.1% |
|
| Sepsis |
12.3% |
| Vomiting |
10.3% |
| Pulmonary Embolism |
8.9% |
| Pneumonia |
6.8% |
| Pyrexia |
6.2% |
| Pleural Effusion |
5.5% |
| Thrombocytopenia |
5.5% |
| Diarrhoea |
4.8% |
| Febrile Neutropenia |
4.8% |
| Myelodysplastic Syndrome |
4.1% |
| Neutropenic Infection |
4.1% |
| Dyspnoea |
3.4% |
| Somnolence |
3.4% |
| Wrong Technique In Drug Usage Process |
3.4% |
| Neutropenia |
2.7% |
| Neutropenic Sepsis |
2.7% |
| Noctiphobia |
2.7% |
| Respiratory Failure |
2.7% |
| Toxicity To Various Agents |
2.7% |
| Urinary Tract Infection |
2.7% |
|
| Concomitant |
| Product Used For Unknown Indication |
21.8% |
| B-cell Lymphoma |
9.6% |
| Drug Use For Unknown Indication |
8.8% |
| Prophylaxis |
8.2% |
| Chronic Lymphocytic Leukaemia |
5.5% |
| Mantle Cell Lymphoma |
4.7% |
| Prophylaxis Of Nausea And Vomiting |
4.4% |
| Rhabdomyosarcoma |
4.0% |
| Sarcoma |
4.0% |
| Diffuse Large B-cell Lymphoma |
3.5% |
| Plasma Cell Myeloma |
3.3% |
| T-cell Lymphoma |
3.2% |
| Aplastic Anaemia |
3.1% |
| Lymphoma Aids Related |
2.8% |
| Neuroblastoma |
2.7% |
| Bone Marrow Conditioning Regimen |
2.5% |
| Antifungal Prophylaxis |
2.1% |
| Prophylaxis Against Graft Versus Host Disease |
2.0% |
| Pain |
2.0% |
| Acute Myeloid Leukaemia |
1.9% |
|
| Myelodysplastic Syndrome |
10.3% |
| Infection |
9.0% |
| Vomiting |
9.0% |
| Drug Ineffective |
6.5% |
| Skin Cancer |
6.5% |
| Cytomegalovirus Infection |
5.2% |
| Neoplasm |
5.2% |
| White Blood Cell Count Decreased |
5.2% |
| Mucosal Inflammation |
4.5% |
| Neutropenic Infection |
4.5% |
| Sepsis |
4.5% |
| Thrombocytopenia |
4.5% |
| Febrile Neutropenia |
3.9% |
| Respiratory Failure |
3.9% |
| Neutropenia |
3.2% |
| Neutropenic Sepsis |
3.2% |
| Squamous Cell Carcinoma Of Skin |
3.2% |
| Nephropathy Toxic |
2.6% |
| Off Label Use |
2.6% |
| Tumour Flare |
2.6% |
|
